Evidence map›Paper›PMID 25990251›Full record

ArticleJournal of translational medicine2015

Identification and selective expansion of functionally superior T cells expressing chimeric antigen receptors.

ZeNan L Chang, Pamela A Silver, Yvonne Y Chen

Open access · goldAbstract read
In one paragraph

Article in Journal of translational medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Engineering T cells for immunotherapy of primary human hepatocellular carcinoma.Journal of genetics and genomics = Yi chuan xue bao · 2020
    Review
  10. Article
  11. Article
  12. Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory.Proceedings of the National Academy of Sciences of the United States of America · 2018
    Article
  13. Influence of various medium environment to in vitro human T cell culture.In vitro cellular & developmental biology. Animal · 2018
    Article
  14. Article
  15. Review
  16. Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy.Journal of the National Cancer Institute · 2016
    Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

ZeNan L ChangDepartment of Chemical and Biomolecular Engineering, University of California-Los Angeles, 420 Westwood Plaza, Boelter Hall 5531, Los Angeles, CA, 90095, USA. zenan.chang@ucla.edu.
Pamela A SilverDepartment of Systems Biology, Harvard Medical School, 200 Longwood Avenue, WAB 563, Boston, MA, 02115, USA. pamela_silver@hms.harvard.edu.
Yvonne Y ChenDepartment of Chemical and Biomolecular Engineering, University of California-Los Angeles, 420 Westwood Plaza, Boelter Hall 5531, Los Angeles, CA, 90095, USA. yvonne.chen@ucla.edu.
University of California, Los Angeles · USCenter for Systems Biology · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MITSUYASU, RONALD T. · 1991 to 2018
$39.9M
UCLA-Caltech Medical Scientist Training ProgramT32GM008042 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI AJIJOLA, OLUJIMI A, DAWSON, DAVID WAYNE · 1985 to 2023
$29.9M
Systems in Integrative BiologyT32GM008185 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHOU, TOM · 1987 to 2022
$4.6M
TRANSPORT OF PROTEINS IN AND OUT OF THE NUCLEUSR01GM036373 · NIGMS · PRINCETON UNIVERSITY · PI SILVER, PAMELA A · 1986 to 2016
$2.5M
Engineering of computational receptors and gene circuits for T-cell immunotherapyDP5OD012133 · OD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHEN, YVONNE YU-HSUAN · 2012 to 2016
$1.7M
Engineering robust adoptive T-cell cancer therapy by rewiring TGF-beta signalingF30CA183528 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHANG, ZENAN L · 2014 to 2016
$134k
NCI NIH HHS F30 CA183528NCI NIH HHS P30 CA016042NIAID NIH HHS P30 AI028697NIGMS NIH HHS R01 GM036373NIGMS NIH HHS T32 GM008042NIGMS NIH HHS T32 GM008185NIH HHS DP5 OD012133
6 · The paper itself

Abstract

backgroundT cells expressing chimeric antigen receptors (CARs) have shown exciting promise in cancer therapy, particularly in the treatment of B-cell malignancies. However, optimization of CAR-T cell production remains a trial-and-error exercise due to a lack of phenotypic benchmarks that are clearly predictive of anti-tumor functionality. A close examination of the dynamic changes experienced by CAR-T cells upon stimulation can improve understanding of CAR-T-cell biology and identify potential points for optimization in the production of highly functional T cells.

methodsPrimary human T cells expressing a second-generation, anti-CD19 CAR were systematically examined for changes in phenotypic and functional responses to antigen exposure over time. Multi-color flow cytometry was performed to quantify dynamic changes in CAR-T cell viability, proliferation, as well as expression of various activation and exhaustion markers in response to varied antigen stimulation conditions.

resultsStimulated CAR-T cells consistently bifurcate into two distinct subpopulations, only one of which (CAR(hi)/CD25(+)) exhibit anti-tumor functions. The use of central memory T cells as the starting population and the resilience-but not antigen density-of antigen-presenting cells used to expand CAR-T cells were identified as critical parameters that augment the production of functionally superior T cells. We further demonstrate that the CAR(hi)/CD25(+) subpopulation upregulates PD-1 but is resistant to PD-L1-induced dysfunction.

conclusionsCAR-T cells expanded ex vivo for adoptive T-cell therapy undergo dynamic phenotypic changes during the expansion process and result in two distinct populations with dramatically different functional capacities. Significant and sustained CD25 and CAR expression upregulation is predictive of robust anti-tumor functionality in antigen-stimulated T cells, despite their correlation with persistent PD-1 upregulation. The functionally superior subpopulation can be selectively augmented by careful calibration of antigen stimulation and the enrichment of central memory T-cell type.

Indexed as

Antigens, CDB7-H1 AntigenCell Line, TumorCell ProliferationGene DosageHumansImmunologic MemoryLymphocyte ActivationLymphocyte SubsetsPhenotypeProgrammed Cell Death 1 ReceptorReceptors, Antigen, T-CellT-LymphocytesTransgenesUp-RegulationAntigens, CDB7-H1 AntigenCD274 protein, humanPDCD1 protein, humanProgrammed Cell Death 1 ReceptorReceptors, Antigen, T-Cell

Identifiers

PMID25990251
PMCPMC4457995
OpenAlexW2166729052

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.